Abstract
Inflammatory bowel disease (IBD) increases the risk of colitis-associated cancer (CAC). Evidences suggest that Helicobacter pylori (H. pylori) infection is associated with a low risk of IBD and protects against experimental colitis in mouse models. However, the effect of H. pylori infection in CAC remains unclear. We previously reported that H. pylori infection increased M2 macrophages in dextran sodium sulfate (DSS)-induced chronic colitis. Tumor-associated macrophages (TAMs) play a pivotal role in colon cancer. Therefore, we established a H. pylori-infected CAC mouse model induced by azoxymethane and DSS to explore the effect of H. pylori infection on TAMs in CAC. Here, we demonstrated that H. pylori infection attenuated the development of CAC by decreasing tumor multiplicity, tumor size, tumor grade and colitis scores. Moreover, H. pylori infection reduced the infiltration of TAMs, particularly M2-like TAMs in CAC tumors, accompanied with the down-regulated pro-inflammatory and pro-tumorigenic factors TNF-α, IL-1β, IL-6 and IL-23 in tumors of CAC mice. Our study suggests that H. pylori infection can reduce TAMs infiltration and regulate cytokines expression in CAC.
References
Mar 15, 2001·Gut·J A EadenJ F Mayberry
Apr 14, 2006·Alimentary Pharmacology & Therapeutics·C CanavanJ Mayberry
Oct 20, 2007·Nature Protocols·Benno WeigmannMarkus F Neurath
Apr 8, 2010·Cell·Bin-Zhi Qian, Jeffrey W Pollard
May 3, 2011·Gastroenterology·Thomas A Ullman, Steven H Itzkowitz
Nov 19, 2011·Cancer Cell·Md Hasan ZakiThirumala-Devi Kanneganti
Feb 2, 2012·American Journal of Epidemiology·Yan ZhangHermann Brenner
Mar 22, 2014·Molecular Cancer Therapeutics·Yun DaiLiang Qiao
Apr 29, 2014·Journal of Translational Medicine·Xiaochang LinXuegang Sun
Aug 16, 2014·Cancers·Theerawut ChanmeeNaoki Itano
Dec 2, 2014·Molecular Medicine Reports·Wei WangShourong Shen
Mar 17, 2015·Trends in Immunology·Renato OstuniGioacchino Natoli
Apr 29, 2015·Matrix Biology : Journal of the International Society for Matrix Biology·Elena I Deryugina, James P Quigley
Jan 23, 2016·Oncotarget·Ting WuLiang Qiao
Jan 25, 2017·Nature Reviews. Clinical Oncology·Alberto MantovaniPaola Allavena
Feb 16, 2017·Mediators of Inflammation·Gabor J SzebeniLaszlo G Puskas
Mar 1, 2017·Journal of Hematology & Oncology·Li Yang, Yi Zhang
Apr 30, 2017·Advanced Drug Delivery Reviews·Chayanon NgambenjawongSuzie H Pun
May 26, 2017·Current Opinion in Pharmacology·Nathalie DehneBernhard Brüne
Nov 2, 2017·Oncotarget·Yi-Zhong WuFa-Chao Zhi
May 23, 2018·Inflammatory Bowel Diseases·Hongchen ZhangWeihong Wang
Dec 24, 2018·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Kun-Der LinJohn Y Kao
Aug 5, 2019·Inflammation·Xia LiJingtong Wang
Oct 31, 2019·Cancer Biology & Therapy·Han LiLixin Sun
Feb 8, 2020·Clinical and Translational Gastroenterology·Da Sol ChoiChan Hyuk Park
Apr 3, 2020·European Journal of Pharmacology·Chen YunnaChen Weidong